Earnings Call · Q2 FY2023·2023-08-03

Q2 23EPS -37.50%·Rev n/aQ1 23EPS -6.25%·Rev n/aQ4 22EPS -23.08%·Rev n/aQ3 22EPS +7.14%·Rev n/a⚠ consensus missing

LEXICON PHARMACEUTICALS, INC. LXRX

Carrie Siragusa — Investor Relations

Lonnel Coats — Chief Executive Officer

Jeffrey Wade — President and Chief Financial Officer

Craig Granowitz — Chief Medical Officer

−2.6%1d on move date−2.2% vs SPY3d−5.2%5d−10.4%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more LXRX calls or request research access.

More LXRX calls Browse calls Request research access